Compare · MRUS vs NVO
MRUS vs NVO
Side-by-side comparison of Merus N.V. (MRUS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRUS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 190.6x MRUS ($1.01B).
- NVO has hit the wire 7 times in the past 4 weeks while MRUS has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 17 for MRUS).
- Company
- Merus N.V.
- Novo Nordisk A/S
- Price
- $90.00-7.15%
- $42.94-1.84%
- Market cap
- $1.01B
- $191.82B
- 1M return
- -6.32%
- -
- 1Y return
- +64.05%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 0
- 7
- Recent ratings
- 17
- 25
Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MRUS
- FDA Approval for BIZENGRI issued to MERUS N.V.
- FDA Approval for BIZENGRI issued to MERUS N.V.
- LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
- LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
- EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
- SEC Form 15-12G filed by Merus N.V.
- Amendment: SEC Form SCHEDULE 13D/A filed by Merus N.V.
- Amendment: SEC Form 25-NSE/A filed by Merus N.V.
- Merus N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders
- Amendment: SEC Form SC 14D9/A filed by Merus N.V.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates